Company asks FDA to approve ferric citrate for iron deficiency anemia in patients with non-dialysis dependent chronic kidney disease.
In a study, 61% of hemodialysis patients reported accidentally forgetting to take their medication or otherwise skipping doses unintentionally.
The phosphate binder is a useful treatment for hyperphosphatemia with a relatively low pill burden, researchers say.
Phosphorus targets in patients with chronic kidney disease stage 3 to 4 should be below 4.3 mg/dL, researchers report.
Hyperphosphatemia is present in many who say following diets and binder schedules is easy.
Autonomy support could be an appropriate target for culturally informed strategies to optimize mineral bone health.
A mortality rate increase of 43 cases per 1000 patients was found for calcium-based phosphate binders.
Researchers observe an 81% increase in dialysis patients achieving recommended phosphorus levels after switching to sucroferric oxyhydroxide.